As per Future Market Insights’ latest industry analysis, valuation of the global Cell Therapy Manufacturing Market was around US$ 3.3 Bn in 2021, and is projected to exhibit a CAGR of close to 14.2% over the forecast period. The market is expected to reach US$ 13.9 Bn in 2032.
Cell therapies are utilized widely to treat viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. Introduction of reagents and closed system automated equipment for the manufacturing of cellular therapies is an outcome of the increasing research activities in the field of such therapies.
Get a Sample PDF Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-15536
A decentralized manufacturing model for clinical trials in cell therapies engaging multiple sites are being favored across the globe. Such instances advocate the treatment of patients using cells, which are produced by utilizing automated equipment at each participating center by considering a single, centrally held investigational new drug application (IND).
Many academic centers are nowadays investing in the development of such automated devices for point-of-care manufacturing and engagement in decentralized multi-center clinical trials. The global cell therapy manufacturing market would thus observe a boom in the next decade. Besides, introduction of novel therapies licensed by regulatory bodies for targeted therapeutic approach would further propel the overall growth in the market during the projected period.
Key Takeaways from Market Study
- By source, the autologous segment held a global market share of about 56.0% in 2021.
- Based on indication, the cancer segment held nearly 31.0% in 2021 in the cell therapy manufacturing market.
- In terms of purpose, the clinical segment accounted for around 42.0% of the global market share in 2021.
- Injectable route of administration of cell therapies generated a global market share of around 44.0% in 2021.
- By cell type, the hematopoietic stem cells (HSC) segment held a share of around 25.0% in the global cell therapy manufacturing market in 2021.
- By end use, the hospital settings category generated a share of around 38.1% in 2021 in the global cell therapy manufacturing market.
- China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market.
“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,” says an analyst of Future Market Insights.
Contact Us for a Discount: https://www.futuremarketinsights.com/request-discount/rep-gb-15536
Competitive Landscape: Cell Therapy Manufacturing Market
Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.
For instance,
- In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify transition from clinical development to commercial manufacturing among cell therapy developers.
- Charles River Laboratories’ Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.
Get Exclusive Insights on Cell Therapy Manufacturing Market
Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Key Players:
- Merck KGaA
- Avantor, Inc.
- Cell Therapies Pty Ltd
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- BIOCENTRIQ
- FUJIFILM Diosynth Biotechnologies
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- WuXi AppTec.
- OXGENE
- Pharmaron
- Aldevron
- FLODESIGN SONICS
- Exothera
Customization Available Upon Request: https://www.futuremarketinsights.com/customization-available/rep-gb-15536
Key Segments Covered in Cell Therapy Manufacturing Industry
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
